Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Clearside Biomedical Inc    CLSD

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/16/2018 01/17/2018 01/18/2018 01/19/2018 01/22/2018 Date
6.24(c) 6.14(c) 6.22(c) 6.44(c) 6.22 Last
148 664 118 417 64 495 111 884 121 357 Volume
-1.73% -1.60% +1.30% +3.54% -3.42% Change
More quotes
Financials ($)
Sales 2017 0,26 M
EBIT 2017 -59,9 M
Net income 2017 -60,3 M
Finance 2017 43,7 M
Yield 2017 -
Sales 2018 0,07 M
EBIT 2018 -68,1 M
Net income 2018 -68,4 M
Debt 2018 3,76 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 454x
EV / Sales2018 2 503x
Capitalization 163 M
More Financials
Company
Clearside Biomedical, Inc. is a clinical stage biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011... 
More about the company
Surperformance© ratings of Clearside Biomedical Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on CLEARSIDE BIOMEDICAL INC
2017 Clearside Biomedical, Inc. to Present at the 36th Annual J.P. Morgan Healthca..
2017 CLEARSIDE BIOMEDICAL : to Participate in Stifel 2017 Healthcare Conference
2017 Clearside Biomedical, Inc. to Participate in Stifel 2017 Healthcare Conferenc..
2017 Clearside Biomedical’s Phase 1/2 Open Label Clinical Trial of CLS-TA Wi..
2017 CLEARSIDE BIOMEDICAL : Management's Discussion and Analysis of Financial Conditi..
2017 CLEARSIDE BIOMEDICAL, INC. : Results of Operations and Financial Condition, Fina..
2017 Clearside Biomedical, Inc. Announces Third Quarter 2017 Financial Results and..
2017 CLEARSIDE BIOMEDICAL INC : Clearside Biomedical, Inc. to Host Earnings Call
2017 BANK OF NEW YORK MELLON : Has $852,000 Holdings in Clearside Biomedical, Inc. (C..
2017 CLEARSIDE BIOMEDICAL, INC. (NASDAQ : CLSD) Files An 8-K Entry into a Material De..
More news
Sector news : Bio Therapeutic Drugs
10:25p Stocks hit record as senators reach deal to end shutdown
07:59p Big Drugmakers Pay Big Prices for Promising Biotechs
06:16p Dealmaking drives European stocks as equity melt-up continues
05:23p Biotech M&A takes off as Sanofi and Celgene spend $20 billion
05:05p CELGENE : to Buy Juno Therapeutics for $9 Billion -- 2nd Update
More sector news : Bio Therapeutic Drugs
Latest Tweets
01/21Dana White, Daniel Cormier expect fireworks between Stipe Miocic and Francis .. 
01/16Want the latest analyst ratings on $KRNT $HALL $HAFC $CLSD $TIER? Get Them De.. 
01/13$CLSD - Clearside Biomedical #CLSD Receiving Somewhat Favorable Press Coverag.. 
01/13Clearside Biomedical $CLSD Receiving Somewhat Favorable Press Coverage, Repor.. 
2017Clearside Biomedical, Inc. to Present at the 36th Annual J.P. Morgan Healthca.. 
More tweets
Qtime:111
News from SeekingAlpha
2017 Midday Gainers / Losers
2017 NASDAQ BIOTECH INDEX : 54 to be added, 15 removed
2017 YOUR DAILY PHARMA SCOOP : Celgene Upside, Erytech Tumbles, Novartis Neulasta Bio..
2017 YOUR DAILY PHARMA SCOOP : Gilead CAR-T Potential, Egalet Surges, Aerie Launches ..
2017 Clearside Biomedical (CLSD) Presents At Stifel 2017 Healthcare Conference - S..
Chart CLEARSIDE BIOMEDICAL INC
Duration : Period :
Clearside Biomedical Inc Technical Analysis Chart | CLSD | US1850631045 | 4-Traders
Technical analysis trends CLEARSIDE BIOMEDICAL INC
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 20,3 $
Spread / Average Target 214%
EPS Revisions
Managers
NameTitle
Daniel H. White President, Chief Executive Officer & Director
Christy L. Shaffer Independent Chairman
Charles A. Deignan CFO & Principal Accounting Officer
Glenn Noronha Chief Scientific Officer
Richard L. Beckman Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
CLEARSIDE BIOMEDICAL INC-8.00%163
GILEAD SCIENCES13.04%105 754
VERTEX PHARMACEUTICALS5.41%39 951
REGENERON PHARMACEUTICALS-1.18%39 917
GENMAB13.75%11 762
EXELIXIS, INC.-7.89%8 284